Find in Library

S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX

oleh: John Mascarenhas, Tania Jain, Salman Otoukesh, Aaron T. Gerds, Alessandro Lucchesi, Iberia Romina Sosa, Kamel Laribi, Elena Mishchenko, Atanas Radinoff, Giulia Benevolo, Alessandro M. Vannucchi, Francoise Boyer, Philippe Quittet, Markus Radsak, Antoine Machet, Prithviraj Bose, Zhuying Huang, Hope Qamoos, Jesse Mcgreivy, Wayne P. Rothbaum, Srdan Verstovsek, Francesco Passamonti